Halloran P F, Madrenas J
Department of Medicine, Edmonton, Alberta, Canada.
Clin Biochem. 1991 Feb;24(1):3-7. doi: 10.1016/0009-9120(91)90063-k.
The introduction of cyclosporine (CyA) as a pharmacological agent has resulted not only in a dramatic improvement in the clinical management of transplant recipients but also in a better understanding of the molecular basis of the immune response, especially T cell function. Knowledge of the mechanism of action of CyA has led to exciting areas of study. Among these are the sequence of regulatory events leading to T cell activation, the potential relevance of isomerases in signal transduction pathways (as the receptor for CyA, cyclophilin has been shown to be an isomerase), the blocking effect of CyA on the development of multidrug resistance, and the striking parallelism between CyA and the newer immunosuppressive agent FK-506. These fields promise to be relevant in solving some of the crucial questions in transplantation immunology, and developing better strategies for immunosuppression.
环孢素（CyA）作为一种药物的引入，不仅显著改善了移植受者的临床管理，还增进了我们对免疫反应分子基础的理解，尤其是T细胞功能。对CyA作用机制的了解引发了令人兴奋的研究领域。其中包括导致T细胞活化的调节事件序列、异构酶在信号转导途径中的潜在相关性（作为CyA的受体，亲环蛋白已被证明是一种异构酶）、CyA对多药耐药性发展的阻断作用，以及CyA与新型免疫抑制剂FK-506之间惊人的相似性。这些领域有望在解决移植免疫学中的一些关键问题以及制定更好的免疫抑制策略方面发挥作用。
